Nikki Rendon

doctorate of behavioral neuroendocrinology. covering rheumatology. fierce feminista. environmentalist. rescuer of cats and greyhounds. she/her.

[NPR @NPR]

As many of us start to emerge from isolation, what "firsts" are you're looking forward to? https://t.co/64IIk5ggeZ

[Nikki Rendon @RendonNikki]

https://t.co/pRSKl7NUSg

[Dr. John Cush @RheumNow]

RNL 2021: EULAR 2019 and ACR 2020 RA Treatment Guidelines - Dr. Alan Matsumoto

Dr. Alan Matsumoto presents EULAR 2019 and ACR 2020 RA Treatment Guidelines at the 2021 RheumNow Live meeting.

https://t.co/1swZIWGWKc

[Dr. John Cush @RheumNow]

RNL 2021 - Assessing Psoriasis: Melodie Young, MSN, ANP-c

https://t.co/ZzOnJOtKjz

[Dr. John Cush @RheumNow]

Increased Methotrexate Liver Disease in Psoriasis

https://t.co/sEZajDIkSz

[Dr. John Cush @RheumNow]

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy

Analysis of patients receiving TNFi therapy in the BSRBR shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy.

https://t.co/oHJXOa96Kn

[Dr. John Cush @RheumNow]

2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt

[Dr. John Cush @RheumNow]

News Feature: Low IBD Risk with IL-17 Inhibition

https://t.co/1kUH7sP755

[Dr. John Cush @RheumNow]

Free read on the 20 year history, immunology and targeting of interleukin-17 (IL-17) Great article by Professor Pierre Miossec https://t.co/69acTuPWZZ

[Dr. John Cush @RheumNow]

The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease

Sponsored by Novartis Medical Affairs

Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020.

View Now: https://t.co/rxTAwQNalx

[Dr. John Cush @RheumNow]

RheumNow Live starts one week from today!

The 2021 RheumNow Live current speaker list includes:
Roy Fleischmann, Clay Cockerell, Eric Ruderman, Alexis Ogdie, Philip Robinson, Jeff Sparks, Nigel Haroon, Artie Kavanaugh, and Jack Cush.

Register today.
https://t.co/Woxi4Ri0O5

[Dr. John Cush @RheumNow]

News Feature: NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

https://t.co/IrKnTlPDpK

[The Lancet @TheLancet]

"Bimekizumab might be our most effective biologic for psoriasis yet," write William Huang & Steven Feldman. But should we be offering it as a first-line treatment for everyone with severe psoriasis? Read the Comment. https://t.co/HkKjC4o2eg

[Joel M Gelfand MD MSCE FAAD @DrJoelGelfand]

83 new #psoriasis #PubMed hits this wk. Highlighting this Phase 3 trial of #bimekizumab in @TheLancet. Nearly 60% achieved PASI100 at week 16. High rate of #candidiasis (15% over 52 wks) and 1 patient developed #inflammatoryboweldisease @AADmember
https://t.co/IhWrk9EqEE

[Joel M Gelfand MD MSCE FAAD @DrJoelGelfand]

65 new #psoriasis #PubMed hits. Highlighting this #Cochrane meta-analysis of systemic pso tx. The #biologics #infliximab #ixekizumab #risankizumab #bimekizumab #guselkumab #secukinumab and #brodalumab were the best for achieving PASI90 at 8-24 wks https://t.co/uujgMnpQDY

[Joseph Merola, MD MMSc @JosephMerolaMD]

The Lancet: Phase 3 data from the IL17A/F inhibitor bimekizumab in psoriasis; anxiously awaiting on-going phase 3 data in PsA which is of particular interest given the impressive phase 2 in PsA @bwhdermatology https://t.co/C6Etuw2Ysc

[Joseph Merola, MD MMSc @JosephMerolaMD]

Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: Delphi consensus study - We hope these will help support research efforts at the key PsO-PsA interface of early / preclinical disease ⁦@bwhdermatology⁩ https://t.co/uIJDaSGVvu

[Joseph Merola, MD MMSc @JosephMerolaMD]

Lancet: Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial ⁦@bwhdermatology⁩ #psoriaticarthritis #psoriasis https://t.co/9hosnpm7W2

[Dr. John Cush @RheumNow]

On March 24, 2021 the FDA Arthritis Advisory Committee and Drug Safety .... Committees will meet online to will discuss biologics license application, for tanezumab, from Pfizer, for the proposed treatment of moderate to severe osteoarthritis in adults https://t.co/NSlutqdHzu